{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Class (Stereo):
CHEMICAL (ACHIRAL)
Enpiprazole is a heterocyclic three-ringed pyrazolylalkyl piperazine derivative. Enpiprazole has a cataleptic action very similar to that of neuroleptics, and its effect on muscle relaxation is comparable with that of diazepam. Enpiprazole exerts anxiolytic properties in animals.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Tasuldine is as an orally active bronchosecretolytic agent that was clinically effective in human. However, information about the further development and use of this drug is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Belarizine was studied as a cerebral vasodilator.
Status:
Investigational
Source:
INN:tisocalcitate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tisocalcitate is the vitamin D derivative. Tisocalcitate ointment is currently in phase 2 clinical development for mild to moderate psoriasis. Early studies have shown that, unlike other vitamin D3 analogues, tisocalcitate does not affect calcium metabolism. Tisocalcitate ointments were tolerated well and were safe to use on healthy skin. Tisocalcitate had been in phase II clinical trial for the treatment of psoriasis. However, this development was discontinued.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Nemifitide is a peptide analog of melanocyte-inhibiting factor (MIF) that has been reported to relieve depressive symptoms in a very short period. Tetragenex (formerly Innapharma) was developing nemifitide with potential in the treatment of depression. Clinical data obtained from two pilot clinical studies, double-blind, placebo-controlled, parallel-design, in-patient and outpatient, suggested that nemifitide may have the following advantages over current therapies: rapid onset of action (3–5 d), short period of administration (5–10 doses over a 1–2 wk period), and a relatively long duration of treatment effect (3–6 months). The mechanism of action of nemifitide was investigated by evaluating its in-vitro receptor binding and in-vivo localization in the rat brain as well as its interactions with psychoprobes indicative of specific neurotransmitter pathways in acute studies in rats. The results of these studies indicate that nemifitide readily crosses the blood–brain barrier and is localized mainly in the amygdala, hippocampus and frontal cortex of the rat brain. Its in-vitro binding to several receptors including 5-HT-2A, as well as its significant interaction with d-fenfluramine in the rat, suggest the participation of the serotonergic pathway in its mode of action in a different way than that observed with SSRI antidepressants.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (RACEMIC)
Adicillin (Penicillin N) is a penicillin derivative produced by Cephalosporium acremonium. Adicillin is dextrorotatory. Inactivated by penicillinase as is penicillin G, but differs from the common penicillin by its antibacterial activity and hydrophilic character. Active against Sarcina lutea, Proteus vulgaris, Salmonella typhimurium, Diplococcus pneumoniae. Shows practically no activity against B. subtilis and Staph. aureus. The toxicity is somewhat less than that of penicillin G, although penicillin N is excreted more slowly.
Status:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Chloroserpidine is deserpidine derivative with hypotensive and sedative action
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Tabimorelin is an orally active and selective growth hormone secretagogue (GHS) that was derived from growth hormone-releasing peptide-1(GHRP-1) via ipamorelin by a peptidomimetic approach. Tabimorelin inhibits both on gut and liver CYP3A4 activity. Tabimorelin has been in phase II clinical trials for the treatment of somatotropin deficiency. However, this research has been discontinued because the majority of growth hormone deficient adults did not respond to Tabimorelin.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)